Andrew Minchinton obtained a PhD in Radiation Biology at the Middlesex Hospital Medical School/University College London and Gray Laboratory in the UK. After a post-doctoral fellowship in Vancouver he was recruited to Stanford University by J. Martin Brown as a staff scientist. After 3 years in California and somewhat bored in Palo Alto, he was recruited back to Vancouver and is now a Distinguished Scientist in the Department of Integrative Oncology and Head of the Radiation Biology Unit. At the University of British Columbia (UBC) he holds a faculty appointment in Pathology & Laboratory Medicine, the Medical Physics Graduate Program and teaches Radiation Biophysics in the Department of Physics and Astronomy.
Major interests include how the tumour microenvironment influences radiotherapy outcome with particular interest in oxygen and the electron transport chain, extravascular drug distribution and DNA damage repair and drug discovery. Most recently focus has been on translational developments to discover a cancer targeted inhibitor of a pivotal DNA repair proteins as well as fundamental experiments on FLASH radiotherapy.
Dr. Minchinton has received over $20M in peer-reviewed operating grants, has published over 100 peer-reviewed articles (which have been cited over 6000 times). He has 6 patents including a library of over 1000 new chemical entities related to DNA-PK inhibitors and currently holds two CIHR operating grants. His recent accolades include the Robert F. Kallman award for academic leadership, scientific excellence, service to the profession and commitment to colleagues, students and Stanford University.